Results 171 to 180 of about 516,933 (343)

An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population

open access: yesClinical Anatomy, EarlyView.
ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley   +1 more source

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

open access: yesJournal of Clinical Oncology, 2015
N. Ahmed   +25 more
semanticscholar   +1 more source

Lactylation in cancer biology: Unlocking new avenues for research and therapy

open access: yesCancer Communications, EarlyView.
Abstract Lactylation, a newly identified post‐translational modification, plays a multifaceted role in cancer biology by integrating epigenetic and non‐epigenetic mechanisms. This review summarizes the latest research progress on lactylation, including its functions in epigenetic regulation and its broader impact on cellular processes.
Xiaoyu Hou   +6 more
wiley   +1 more source

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

open access: yesCancer Communications, EarlyView.
Abstract Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 (KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).
Jian Li   +31 more
wiley   +1 more source

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

open access: yesJournal of Clinical Oncology, 2011
P. Robbins   +20 more
semanticscholar   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

open access: yesCancer Communications, EarlyView.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy